Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma

References

• DeVita V T, Jr, Canellos G P, Chabner B, Schein P, Hubbard S P, Young R C. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1975; 1: 248–250
   PubMed Web of Science ®Google Scholar
• Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, et al. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol 1994; 5: 91–95
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Rambaldi A, Rossi A, Oldani E, Ghielmini M, Benedetti F, et al. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. Br J Haematol 2001; 114: 333–341
   PubMed Web of Science ®Google Scholar
• Gordon L I, Harrington D, Andersen J, Colgan J, Glick J, Neiman R, et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342–1349
   PubMed Web of Science ®Google Scholar
• Montserrat E, Garcia-Conde J, Vinolas N, Lopez-Guillermo A, Hernandez-Nieto L, Zubizarreta A, et al. CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial (PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology). Eur J Haematol 1996; 57: 377–383
   PubMed Web of Science ®Google Scholar
• Drenou B, Amiot L, Lamy T, Le Prise P Y, Fauchet R. Multidrug resistance in aggressive lymphoproliferative disorders of T and natural-killer origin. Leuk Lymphoma 1998; 30: 381–387
   PubMed Web of Science ®Google Scholar
• Jillella A P, Murren J R, Hamid K K, Longley B J, Edelson R L, Cooper D L. P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma. Cancer Invest 2000; 18: 609–613
   PubMed Web of Science ®Google Scholar
• Liu Q, Ohshima K, Kikuchi M. High expression of MDR-1 gene and P-glycoprotein in initial and re-biopsy specimens of relapsed B-cell lymphoma. Histopathology 2001; 38: 209–216
   PubMed Web of Science ®Google Scholar
• Shepard R L, Cao J, Starling J J, Dantzig A H. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer 2003; 103: 121–125
   PubMed Web of Science ®Google Scholar
• Rubin E H, de Alwis D P, Pouliquen I, Green L, Marder P, Lin Y, et al. A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin Cancer Res 2002; 8: 3710–3717
   PubMed Web of Science ®Google Scholar
• Baer M R, George S L, Dodge R K, O'Loughlin K L, Minderman H, Caligiuri M A, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002; 100: 1224–1232
   PubMed Web of Science ®Google Scholar
• Lacayo N J, Lum B L, Becton D L, Weinstein H, Ravindranath Y, Chang M N, et al. Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia 2002; 16: 920–927
   PubMed Web of Science ®Google Scholar
• Dalton W S. Alternative (non-P-glycoprotein) mechanisms of drug resistance in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 1997; 11: 975–986
   PubMed Web of Science ®Google Scholar
• Leroy K, Haioun C, Lepage E, Le Metayer N, Berger F, Labouyrie E, et al. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 2002; 13: 1108–1115
   PubMed Web of Science ®Google Scholar
• Marie J P, Legrand O. MDR1/P-GP expression as a prognostic factor in acute leukemia. Adv Exp Med Biol 1999; 457: 1–9
   PubMed Web of Science ®Google Scholar
• Kemper E M, Cleypool C, Boogerd W, Beijnen J H, Van Tellingen O. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother Pharmacol 2004; 53: 173–178
   PubMed Web of Science ®Google Scholar
• Callies S, de Alwis D P, Wright J G, Sandler A, Burgess M, Aarons L. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). Cancer Chemother Pharmacol 2003; 51: 107–118
   PubMed Web of Science ®Google Scholar
• Callies S, de Alwis D P, Mehta A, Burgess M, Aarons L. Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979). Cancer Chemother Pharmacol 2004; 54: 39–48
   PubMed Web of Science ®Google Scholar
• Sandler A, Gordon M, De Alwis D P, Pouliquen I, Green L, Marder P, et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res 2004; 10: 3265–3272
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295–1302
   PubMed Web of Science ®Google Scholar
• Fracasso P M, Goldstein L J, de Alwis D P, Rader J S, Arquette M A, Goodner S A, et al. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res 2004; 10: 7220–7228
   PubMed Web of Science ®Google Scholar
• Le L H, Moore M J, Siu L L, Oza A M, MacLean M, Fisher B, et al. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. Cancer Chemother Pharmacol 2005; 56: 154–160
   PubMed Web of Science ®Google Scholar
• Greenberg P L, Lee S J, Advani R, Tallman M S, Sikic B I, Letendre L, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 2004; 22: 1078–1086
   PubMed Web of Science ®Google Scholar
• Gerrard G, Payne E, Baker R J, Jones D T, Potter M, Prentice H G, et al. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica 2004; 89: 782–790
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar